Mangoceuticals, Inc. filed an 8-K on June 10, 2025, reporting the amendment of a $100,000 convertible promissory note with its CEO's trust, converting debt into potential equity at a price of $1.785 per share. Additionally, the company sold 261,667 shares for about $409,367 as part of an equity purchase agreement with Platinum Point Capital under an exemption from registration.